Review
Copyright ©The Author(s) 2021.
World J Stem Cells. Jun 26, 2021; 13(6): 568-593
Published online Jun 26, 2021. doi: 10.4252/wjsc.v13.i6.568
Table 1 Genetic modifications to enhance mesenchymal stem cells potential for treatment of infectious diseases and associated tissue injury
Overexpressed genes
Source of MSCs
Disease model
Experimental Outcome
Ref.
sST2, Ang1, HO1Human AD-MSCs, Mice BM-MSCsLPS-induced ALI mouse modelImproved preservation of lung architecture and reduced inflammationXu et al[77], Martínez-González et al[156], Mei et al[159], Chen et al[160], and Chen et al[220]
TGF-β1Mice BM-MSCsLPS-induced ARDS miceIncreased Treg, induced occludin expression and reduced vascular permeabilityChen et al[160]
IL-10Human UC-MSCsE. coli-induced pneumosepsis mouse modelReduced bacterial load by increasing phagocytosis in macrophagesJerkic et al[75]
Del-1, FGF2Mice BM-MSCsLPS-induced ALI mouse modelReduction in inflammation and lung injuryZhao et al[161], Zhao et al[161,162]
HGFMice BM-MSCsIn vitro LPS treatment of pulmonary endothelial cells Upregulated occludin and reduced permeabilityMeng et al[163]
β-catenin, ROR2, p130/E2F4Mice BM-MSCsLPS-induced ARDS mouse modelHigher retention in lungs and increased differentiation into AT II cellsCai et al [114], Cai et al[121], Zhang et al[114,121,164]
ACE2Mice BM-MSCsLPS-induced ALI mouse modelReduced permeability and lung Ang-II levelsHe et al[166]
CXCR4, EP2 CXCR2Mice BM-MSCsALI/ARDS mouse modelIncreased homing to the site of injuryYang et al [169], Han et al[170], Shen et al[169-171]